Table 3.
Pharmacokinetic Parameters of Irinotecan, SN-38, and SN-38G
| Dose, mg | No. of Patients | Irinotecan AUC0-∞ (h · mg/L) |
Irinotecan CL (L/h) |
SN-38 AUC0-∞ (h · mg/L) |
SN-38G AUC0-∞ (h · mg/L) |
GR |
|||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | SD | Mean | SD | Mean | SD | Mean | SD | Mean | SD | ||
| 400 | 6 | 17.8 | 4.7 | 24.2 | 8.4 | 0.867 | 0.708 | 1.37 | 0.59 | 2.63 | 1.95 |
| 500 | 3 | 35.0 | 17.3 | 18.4 | 12.7 | 1.196 | 0.662 | 3.41 | 2.19 | 2.65 | 0.61 |
| 700 | 30 | 33.8 | 11.8 | 23.3 | 8.5 | 0.808 | 0.655 | 2.76 | 1.96 | 5.17 | 5.06 |
| 850 | 22 | 42.8 | 12.3 | 21.5 | 6.0 | 0.868 | 0.761 | 3.63 | 2.15 | 5.43 | 3.24 |
| 1,000 | 6 | 44.5 | 12.1 | 24.0 | 7.2 | 0.665 | 0.290 | 2.87 | 0.81 | 4.81 | 1.63 |
NOTE. One patient treated at 850 mg had almost identical SN-38G concentrations at 8.5 and 25 hours, resulting in an SN-38G AUC0-∞ of 196.56 h · mg/L and a GR of 178.69, which have been removed from the calculations of the means and SDs in the 850-mg–dose group.
Abbreviations: AUC0-∞, area under the concentration-time curve from zero to infinity; CL, clearance rate; GR, glucuronidation ratio; SD, standard deviation.